



## **Medivation Announces Participation in 12th Annual BIO CEO & Investor Conference**

SAN FRANCISCO, Feb 02, 2010 /PRNewswire via COMTEX News Network/ -- Medivation, Inc. (Nasdaq: MDVN) today announced that David Hung, M.D., president and chief executive officer, will be a featured speaker on a panel entitled, "Alzheimer's Disease: A Panel To Remember," at the 12th Annual BIO CEO & Investor Conference on Tuesday, February 9, at 9:00 a.m. Eastern Time at the Waldorf=Astoria in New York.

Dr. Hung will also provide a corporate update later in the day on Tuesday, February 9, at 11:30 a.m. Eastern Time. During his presentation he will provide an overview of Medivation and its clinical development programs for dimebon (latrepirdine) for Alzheimer's and Huntington diseases and MDV3100 for prostate cancer.

Live audio webcasts of the presentation and panel will be available on the "Events and Presentations" page of the "Investor Relations" section of the Company's website at [www.medivation.com](http://www.medivation.com). A replay also will be available for 30 days following the live presentation.

### **About Medivation**

Medivation, Inc. is a biopharmaceutical company focused on the rapid development of novel small molecule drugs to treat serious diseases for which there are limited treatment options. Medivation aims to transform the treatment of these diseases and offer hope to critically ill patients and their caregivers. In September 2008, Medivation announced a global agreement with Pfizer, Inc to develop and commercialize dimebon (latrepirdine) for the treatment of Alzheimer's and Huntington diseases. With Pfizer, Medivation is conducting a broad dimebon clinical development program that includes several Phase 3 trials assessing the efficacy and safety of dimebon taken alone or in combination with other Alzheimer's medications in patients with mild, moderate and severe Alzheimer's disease. The companies are also conducting a Phase 3 trial of dimebon in Huntington disease. In October 2009, Medivation entered a global agreement with Astellas Pharma Inc. to develop and commercialize MDV3100 for both early- and late-stage prostate cancer. The first Phase 3 clinical trial in the MDV3100 development program, known as the AFFIRM trial, is under way in patients with castration-resistant prostate cancer who have previously been treated with docetaxel-based chemotherapy. For more information, please visit us at [www.medivation.com](http://www.medivation.com).

SOURCE Medivation, Inc.

Copyright (C) 2010 PR Newswire. All rights reserved